Compare CERS & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CERS | EIC |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Finance/Investors Services |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 228.8M |
| IPO Year | 1996 | N/A |
| Metric | CERS | EIC |
|---|---|---|
| Price | $2.84 | $10.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.63 |
| AVG Volume (30 Days) | ★ 2.5M | 103.4K |
| Earning Date | 04-30-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | ★ 27.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,326,000.00 | N/A |
| Revenue This Year | $19.95 | N/A |
| Revenue Next Year | $8.84 | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | ★ 30.68 | N/A |
| 52 Week Low | $1.15 | $9.17 |
| 52 Week High | $3.15 | $13.92 |
| Indicator | CERS | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 64.22 |
| Support Level | $1.84 | $10.37 |
| Resistance Level | $2.91 | $11.34 |
| Average True Range (ATR) | 0.18 | 0.20 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 65.00 | 71.57 |
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.